About Carisma Therapeutics, Inc. - Common Stock (CARM)
Carisma Therapeutics, Inc. is a biotechnology company focused on the development of innovative cell therapies for the treatment of cancer and other diseases. The company specializes in harnessing the power of engineered immune cells, particularly macrophages, to target and destroy tumor cells more effectively. By utilizing advanced genetic engineering techniques, Carisma aims to enhance the body's immune response against cancer, striving to improve patient outcomes and provide novel treatment options for patients with various malignancies. Through research and clinical development, Carisma is dedicated to advancing its therapies toward commercialization and transforming cancer care. Read More
The micro-cap and penny stock arena continues to deliver high-risk, high-reward opportunities, with a dozen companies now gaining attention across the “Mag Penny Undercard” watch list. From emerging technology to biotech, energy, and resource exploration, these under-the-radar plays could be primed for outsized moves this fall.
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
NEW YORK, July 26, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
NEW YORK, July 05, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
BALA CYNWYD, Pa., June 27, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
